Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2016

01.08.2016 | Research Article

Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views

verfasst von: Yishen Wang, Beata Bajorek

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
Literatur
1.
Zurück zum Zitat Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Internet). 2009;7(2):113–23. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Internet). 2009;7(2):113–23.
2.
Zurück zum Zitat Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53(11):1912–20.CrossRefPubMed Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53(11):1912–20.CrossRefPubMed
3.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed
4.
Zurück zum Zitat Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMed Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMed
5.
Zurück zum Zitat Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.CrossRefPubMed Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.CrossRefPubMed
6.
Zurück zum Zitat Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33(4):395–408.CrossRefPubMed Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33(4):395–408.CrossRefPubMed
7.
Zurück zum Zitat Bauer KA. Pros and cons of new oral anticoagulants. Am Soc Hematol Educ Program. 2013;2013:464–70. Bauer KA. Pros and cons of new oral anticoagulants. Am Soc Hematol Educ Program. 2013;2013:464–70.
10.
Zurück zum Zitat Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–354.CrossRefPubMed Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–354.CrossRefPubMed
11.
Zurück zum Zitat You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S–75S.CrossRefPubMedPubMedCentral You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S–75S.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Riva N, Smith DE, Lip GY, Lane DA. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing. 2011;40(6):653–5.CrossRefPubMed Riva N, Smith DE, Lip GY, Lane DA. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing. 2011;40(6):653–5.CrossRefPubMed
13.
Zurück zum Zitat eTG complete [online]. Therapeutic guidelines: cardiovascular, version 6. Melbourne: Therapeutic Guidelines Limited. 2012. eTG complete [online]. Therapeutic guidelines: cardiovascular, version 6. Melbourne: Therapeutic Guidelines Limited. 2012.
14.
Zurück zum Zitat Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefPubMed
15.
Zurück zum Zitat January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):e1–e76.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):e1–e76.CrossRefPubMed
16.
Zurück zum Zitat Bajorek B, Magin P, Hilmer S, Krass I. Contemporary approaches to managing atrial fibrillation: a survey of Australian general practitioners. Australas Med J. 2015;8(11):357–67.CrossRefPubMedPubMedCentral Bajorek B, Magin P, Hilmer S, Krass I. Contemporary approaches to managing atrial fibrillation: a survey of Australian general practitioners. Australas Med J. 2015;8(11):357–67.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19.CrossRefPubMed Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19.CrossRefPubMed
18.
Zurück zum Zitat Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–413.CrossRefPubMed Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–413.CrossRefPubMed
19.
Zurück zum Zitat Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.CrossRefPubMedPubMedCentral Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Bajorek BV, Masood N, Krass I. Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation. Australas J Ageing. 2012;31(2):102–9.CrossRefPubMed Bajorek BV, Masood N, Krass I. Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation. Australas J Ageing. 2012;31(2):102–9.CrossRefPubMed
22.
Zurück zum Zitat Patton M. Qualitative evaluation and research methods. Thousand Oaks, CA: Sage Publications Inc.; 2002. Patton M. Qualitative evaluation and research methods. Thousand Oaks, CA: Sage Publications Inc.; 2002.
24.
Zurück zum Zitat Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.PubMed Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.PubMed
25.
Zurück zum Zitat Devereaux P, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Commentary: varied preferences reflect the reality of clinical practice. BMJ. 2001;323(7323):1218.CrossRefPubMedPubMedCentral Devereaux P, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Commentary: varied preferences reflect the reality of clinical practice. BMJ. 2001;323(7323):1218.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? Understanding senior physicians’ decision-making about anti-thrombotic usage in atrial fibrillation. QJM. 2007;100(5):263–9.CrossRefPubMed Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? Understanding senior physicians’ decision-making about anti-thrombotic usage in atrial fibrillation. QJM. 2007;100(5):263–9.CrossRefPubMed
27.
Zurück zum Zitat Decker C, Garavalia L, Garavalia B, Simon T, Loeb M, Spertus JA, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012;5:129.CrossRefPubMedPubMedCentral Decker C, Garavalia L, Garavalia B, Simon T, Loeb M, Spertus JA, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012;5:129.CrossRefPubMedPubMedCentral
28.
29.
30.
Zurück zum Zitat Vassilikos VP, Mantziari A, Goudis CA, Paraskevaidis S, Dakos G, Giannakoulas G, et al. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hell J Cardiol. 2010;51(2):113–21. Vassilikos VP, Mantziari A, Goudis CA, Paraskevaidis S, Dakos G, Giannakoulas G, et al. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hell J Cardiol. 2010;51(2):113–21.
31.
Zurück zum Zitat Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace. 2015;17(12):1777–86.CrossRefPubMed Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace. 2015;17(12):1777–86.CrossRefPubMed
32.
Zurück zum Zitat Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation: semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11.CrossRefPubMed Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation: semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11.CrossRefPubMed
33.
Zurück zum Zitat Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(5):467–74.CrossRef Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(5):467–74.CrossRef
34.
Zurück zum Zitat Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMed Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMed
35.
Zurück zum Zitat Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.CrossRefPubMed Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.CrossRefPubMed
36.
Zurück zum Zitat De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging. 2010;27(10):807–13.CrossRefPubMed De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging. 2010;27(10):807–13.CrossRefPubMed
37.
Zurück zum Zitat Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMed Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMed
Metadaten
Titel
Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views
verfasst von
Yishen Wang
Beata Bajorek
Publikationsdatum
01.08.2016
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2016
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0329-y

Weitere Artikel der Ausgabe 4/2016

International Journal of Clinical Pharmacy 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.